{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:34:56Z","timestamp":1764509696215,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dankook University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Tumor lysis syndrome (TLS) is a potentially fatal oncological emergency that typically develops during the treatment of rapidly proliferating malignancies. It is infrequently reported in solid tumors, such as pulmonary adenocarcinoma. A 59-year-old male patient with shortness of breath presented with a 3.3 cm \u00d7 3.0 cm mass in the right upper lobe, along with massive right-sided pleural effusion. A percutaneous needle biopsy was performed, and a diagnosis of pulmonary adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation was made. The patient was treated with afatinib because of the malignant pleural effusion and multiple metastases to the intrathoracic lymph nodes, left scapula, and brain. After 4 days of afatinib treatment, he developed oliguric acute kidney injury and progressively worsening dyspnea. Based on the clinical and laboratory findings, the patient was diagnosed with afatinib-induced TLS. To the best of our knowledge, this is the first reported case of afatinib-induced TLS in pulmonary adenocarcinoma.<\/jats:p>","DOI":"10.3390\/medicina59122144","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:56:00Z","timestamp":1702277760000},"page":"2144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-4000","authenticated-orcid":false,"given":"Goohyeon","family":"Hong","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan 31116, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: New therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.14740\/wjon946w","article-title":"Spontaneous tumor lysis syndrome in small-cell lung cancer: A rare complication","volume":"6","author":"Weerasinghe","year":"2015","journal-title":"World J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2006.09.005","article-title":"Tumour lysis syndrome in solid tumours","volume":"18","author":"Gemici","year":"2006","journal-title":"Clin. Oncol. (R Coll Radiol.)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute tumor lysis syndrome in patients with high-grade non-Hodgkin\u2019s lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_6","first-page":"128","article-title":"Spontaneous tumor lysis syndrome in squamous cell carcinoma of the lung","volume":"34","author":"Hussain","year":"2020","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.4081\/rt.2014.5389","article-title":"Tumor lysis syndrome in solid tumors: An up to date review of the literature","volume":"6","author":"Mirrakhimov","year":"2014","journal-title":"Rare Tumors"},{"key":"ref_8","first-page":"e30652","article-title":"Tumor lysis syndrome in patients with solid tumors: A systematic review of reported cases","volume":"14","author":"Alqurashi","year":"2022","journal-title":"Cureus"},{"key":"ref_9","first-page":"105","article-title":"A case of tumor lysis syndrome induced by epidermal growth factor receptor tyrosine kinase inhibitor for lung adenocarcinoma","volume":"63","author":"Eguchi","year":"2017","journal-title":"Osaka City Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"809467","DOI":"10.3389\/fphar.2021.809467","article-title":"Fatal tumour lysis syndrome induced by brigatinib in a lung adenocarcinoma patient treated with sequential ALK inhibitors: A case report","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung Cancer Statistics","volume":"Volume 893","author":"Torre","year":"2016","journal-title":"Lung Cancer and Personalized Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the First Move in EGFR-Driven or ALK-Driven NSCLC: First-Generation or Next-Generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings","volume":"26","author":"Harvey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00000421-199808000-00024","article-title":"Tumor lysis syndrome and acute renal failure after treatment of non-small cell lung carcinoma with combination irinotecan and cisplatin","volume":"21","author":"Persons","year":"1998","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00000421-200010000-00012","article-title":"Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: A case report","volume":"23","author":"Feld","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1385\/MO:22:2:203","article-title":"Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma","volume":"22","author":"Kurt","year":"2005","journal-title":"Med. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2005.02.8753","article-title":"Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer","volume":"24","author":"Ajzensztejn","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1200\/JCO.2011.36.8175","article-title":"Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma","volume":"29","author":"Honda","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03150312","article-title":"Onco-nephrology: Tumor lysis syndrome","volume":"7","author":"Wilson","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08697.x","article-title":"The clinical management of tumour lysis syndrome in haematological malignancies","volume":"154","author":"Will","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1756-8722-5-75","article-title":"Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies","volume":"5","author":"McBride","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:10Z","timestamp":1760132170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["medicina59122144"],"URL":"https:\/\/doi.org\/10.3390\/medicina59122144","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,12,10]]}}}